Health

Nurofen fined $6million for misleading consumers

According to court findings, the brand’s “specific pain” range all contain the same ingredient and do the exact same thing.
Nurofen fined $6million for misleading consumers

Public service announcement: if you’ve ever bought Nurofen’s “Tension Headache” or “Back Pain” tablets, you may want to have a closer look at the product’s packaging.

Earlier this year, the federal government found Reckitt Benckiser, the company responsible for making and marketing Nurofen, guilty of falsely claiming that some of the brand’s products could treat individual types of pain.

The courts found that Nurofen’s “specific pain” range actually contained the same ingredient, meaning that each “specific pain” product did the same as any other within the same range.

Nurofen Back Pain, Nurofen Period Pain, Nurofen Migraine Pain and Nurofen Tension Headache all contain the same active ingredient: ibuprofen lysine 324mg.

As reported by the ABC, Reckitt Benckiser were fined $1.7million – until consumer watchdog, the Australian Competition and Consumer Commission (ACCC) stepped in.

Today, the ACCC have won their appeal of the initial fine, with the federal government upping the price to $6million.

Have you ever brought one of Nurofen’s specifically targeted pain medications? Tell us what you think about this court ruling by commenting on our Facebook page.

Related stories